EcoDrugPlus

Tubulin Beta 4b Class Ivb

Ensembl ID : ENSCHAG00000000203
Gene Symbol: TUBB4B
1 Cross references
130 Possible Orthologues:

Tubulin, Beta 5

Ensembl ID : ENSCHAG00000013461
Gene Symbol: TUBB5
1 Cross references
259 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSCHAG00000019607
Gene Symbol: TP53
1 Cross references
231 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSCHAG00000020604
Gene Symbol: LOC105893205
3 Cross references
145 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSCHAG00000015392
Gene Symbol: TH
3 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSCHAG00000013281
Gene Symbol: TYK2
1 Cross references
196 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSCHAG00000005961
Gene Symbol: LOC105900514
3 Cross references
196 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSCHAG00000026582
Gene Symbol: UTS2R
3 Cross references
92 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like

Ensembl ID : ENSCHAG00000007318
Gene Symbol: LOC105892714
3 Cross references
191 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-2 Subunit

Ensembl ID : ENSCHAG00000003863
Gene Symbol: LOC105891649
3 Cross references
249 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSCHAG00000010673
Gene Symbol: LOC105898700
3 Cross references
192 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSCHAG00000021371
Gene Symbol: LOC105902062
3 Cross references
181 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).